Taken together, these studies highlight the following key findings: (a) Pax2 negatively regulates endometrial cell proliferation in vivo, (b) PAX2-deficient cells outcompete their normal counterparts, and (c) potent synergism between Pax2 and Pten significantly affects cell proliferation and tumor phenotypes. Here, PTEN is linked to neoplasm.